MPG.eBooks - Description: Clinical review report: AbobotulinumtoxinA (Dysport therapeutic) (Ipsen biopharmaceuticals Canada Inc.)

Cover Image

Read Now

Clinical review report: AbobotulinumtoxinA (Dysport therapeutic) (Ipsen biopharmaceuticals Canada Inc.) indication: For the symptomatic treatment of lower-limb spasticity in pediatric patients 2 years of age and older

The objective of this report is to perform a systematic review of the beneficial and harmful effects of abobotulinumtoxinA (aboBoNTA) for the symptomatic treatment of lower-limb spasticity in pediatric patients two years of age and older

Bibliographic Details
Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2018, August 2018
Edition:	Final with redacations
Series:	CADTH common drug review
Subjects:	Cerebral Palsy / Drug Therapy Child Canada Muscle Spasticity / Drug Therapy Neuromuscular Agents Botulinum Toxins, Type A / Therapeutic Use Lower Extremity
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK540260
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The objective of this report is to perform a systematic review of the beneficial and harmful effects of abobotulinumtoxinA (aboBoNTA) for the symptomatic treatment of lower-limb spasticity in pediatric patients two years of age and older
Physical Description:	1 PDF file (130 pages) illustrations